Peter M. Sadow

This study develops antibody-peptide epitope conjugates (APECs) to enhance anti-tumor activity in ICB-resistant HNSCC by leveraging viral peptide-loaded MHC I proteins and protease activity.

This study identifies low HLA/B2M class I expression in ACC tumors and shows it can be reversed by interferon-ψ or STING agonists, suggesting a path for immunotherapy.

The paper generates a multi-modal atlas of thyroid and blood cells from HT, GD, and controls, revealing shared immune niches despite distinct disease mechanisms.

This study investigates the combination of TLR8 agonism and PD-1 blockade in HNSCC patients, finding increased innate immune activation and dendritic cell-T cell interactions.